Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Genmab, Incyte Partner On Trial Of Petosemtamab Combination In KRAS G12D-Mutated ...

24 October 2026 · By · Wire by Fusion42

Published

24 October 2026

Topic

opportunities

◆ Sectors

BiotechDrug Discovery

◆ Geography

EuropeUnited States

◆ Source

Read at rttnews.com →

◆ Verified

Fusion42 · 24 October 2026 · Fusion42 review

Genmab and Incyte have partnered to conduct a clinical trial testing the combination of petosemtamab in patients with KRAS G12D-mutated colorectal cancer, aiming to address a specific genetic mutation in this cancer type.

This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery.

◆ ◆ The Wire takeaway

You can explore new treatment avenues targeting specific cancer mutations as Genmab and Incyte move forward on petosemtamab trials. This partnership opens opportunities in precision oncology drug development.

◆ Coverage

1 source · 24 Oct 2026

◆ Related on Wire

◆ Topics

BiotechDrug Discoveryclinical-trialoncologycolorectal-cancerKRAS-mutationbiotech-partnership